Search results
Results from the WOW.Com Content Network
Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The stock rose more than 4% to close at $143.71. Analysts have been feeling bullish on the stock's prospects for further gains amid big demand for its new Blackwell chips.
For premium support please call: 800-290-4726 more ways to reach us
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. [4] Organon specializes in the following core therapeutic fields: reproductive medicine , contraception , psychiatry , hormone replacement therapy (HRT), and anesthesia .
The S&P 500 is a stock market index maintained by S&P Dow Jones Indices. It comprises 503 common stocks which are issued by 500 large-cap companies traded on the American stock exchanges (including the 30 companies that compose the Dow Jones Industrial Average). The index includes about 80 percent of the American market by capitalization.
A loss of just over 24 percent on May 5, 1893, from 39.90 to 30.02 signaled the apex of the stock effects of the Panic of 1893; the 2007–2008 crash was a 61.8 percent retracement thereof that began on October 11, 2007, and lasted until the closing low on March 9, 2009.
Organon goes public, stock falls in debut. June 3, 2021 at 12:40 PM ...
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.